XML 298 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues:      
Total revenues $ 1,043.6 $ 1,049.3 $ 1,117.5
Operating expenses:      
Research and development 70.7 111.4 188.3
Selling, general and administrative 308.0 368.4 339.5
Amortization of intangible assets 65.1 65.6 59.9
Goodwill impairment 0.0 218.2 6.7
Impairment of long-lived assets 27.2 306.7 0.0
Total operating expenses 1,152.3 1,775.7 1,287.5
Loss from operations (108.7) (726.4) (170.0)
Other income (expense):      
Interest expense (71.0) (87.9) (37.3)
Gain on sale of business 24.3 74.2 0.0
Other, net 12.5 8.9 (11.7)
Total other income (expense), net (34.2) (4.8) (49.0)
Loss before income taxes (142.9) (731.2) (219.0)
Income tax provision (benefit) 47.7 29.3 (7.4)
Net loss $ (190.6) $ (760.5) $ (211.6)
Loss per common share      
Basic (in dollars per share) $ (3.60) $ (14.85) $ (4.22)
Diluted (in dollars per share) $ (3.60) $ (14.85) $ (4.22)
Weighted average shares outstanding      
Basic (in shares) 53.0 51.2 50.1
Diluted (in shares) 53.0 51.2 50.1
Cost of Commercial Product sales      
Revenues:      
Product sales $ 908.7 $ 944.5 $ 966.2
Commercial Product sales      
Revenues:      
Product sales 398.9 497.3 386.6
Operating expenses:      
Cost of goods and services sold [1] 185.9 210.3 160.3
Cost of MCM Product sales      
Revenues:      
Product sales 509.8 447.2 579.6
Operating expenses:      
Cost of goods and services sold [1] 219.4 305.6 264.3
Total Bioservices revenues      
Revenues:      
Total Bioservices revenues 104.9 78.5 109.9
Operating expenses:      
Cost of goods and services sold [1] 276.0 189.5 268.5
Services      
Revenues:      
Product sales 103.5 72.8 105.0
Leases      
Revenues:      
Leases 1.4 5.7 4.9
Contracts and grants      
Revenues:      
Product sales $ 30.0 $ 26.3 $ 41.4
[1]
(1) Exclusive of intangible assets amortization